Loading...
BioCryst Pharmaceuticals, Inc.
BCRX•NASDAQ
Healthcare
Biotechnology
$9.93
$0.01(0.15%)
BioCryst Pharmaceuticals, Inc. (BCRX) Financial Performance & Statements
Review BioCryst Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
36.00%
↑ 36.00%
Operating Income Growth
97.55%
↑ 97.55%
Net Income Growth
60.77%
↑ 60.77%
Operating Cash Flow Growth
45.32%
↑ 45.32%
Operating Margin
6.59%
↑ 6.59%
Gross Margin
96.89%
↑ 96.89%
Net Profit Margin
-10.62%
↓ 10.62%
ROE
11.43%
↑ 11.43%
ROIC
9.75%
↑ 9.75%
BioCryst Pharmaceuticals, Inc. (BCRX) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for BioCryst Pharmaceuticals, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $131.53M | $117.08M | $109.33M | $92.76M |
| Cost of Revenue | $6.13M | $3.23M | $2.05M | $1.26M |
| Gross Profit | $125.40M | $113.86M | $107.28M | $91.50M |
| Gross Profit Ratio | $0.95 | $0.97 | $0.98 | $0.99 |
| R&D Expenses | $49.44M | $41.08M | $37.30M | $46.49M |
| SG&A Expenses | $80.47M | $65.08M | $61.21M | $59.36M |
| Operating Expenses | $129.91M | $106.17M | $98.52M | $105.86M |
| Total Costs & Expenses | $136.04M | $109.39M | $100.57M | $107.12M |
| Interest Income | $3.57M | $3.59M | $3.55M | $4.03M |
| Interest Expense | $24.45M | $24.83M | $24.73M | $24.51M |
| Depreciation & Amortization | $309000.00 | $311000.00 | $320000.00 | $306000.00 |
| EBITDA | -$1.23M | $11.69M | $9.08M | -$10.20M |
| EBITDA Ratio | -$0.009 | $0.10 | $0.08 | -$0.11 |
| Operating Income | -$4.51M | $7.69M | $8.76M | -$14.36M |
| Operating Income Ratio | -$0.03 | $0.07 | $0.08 | -$0.15 |
| Other Income/Expenses (Net) | -$21.48M | -$21.14M | -$21.26M | -$20.53M |
| Income Before Tax | -$25.99M | -$13.45M | -$12.50M | -$35.01M |
| Income Before Tax Ratio | -$0.20 | -$0.11 | -$0.11 | -$0.38 |
| Income Tax Expense | $804000.00 | $586000.00 | $172000.00 | $365000.00 |
| Net Income | -$26.80M | -$14.03M | -$12.67M | -$35.38M |
| Net Income Ratio | -$0.20 | -$0.12 | -$0.12 | -$0.38 |
| EPS | -$0.13 | -$0.07 | -$0.06 | -$0.17 |
| Diluted EPS | -$0.13 | -$0.07 | -$0.06 | -$0.17 |
| Weighted Avg Shares Outstanding | $207.38M | $206.91M | $206.43M | $206.06M |
| Weighted Avg Shares Outstanding (Diluted) | $207.38M | $206.91M | $206.43M | $206.06M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan